PMID- 35680009
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220818
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 182
DP  - 2022 Aug
TI  - Beneficial effects of probiotic and synbiotic supplementation on some 
      cardiovascular risk factors among individuals with prediabetes and type 2 
      diabetes mellitus: A grade-assessed systematic review, meta-analysis, and 
      meta-regression of randomized clinical trials.
PG  - 106288
LID - S1043-6618(22)00233-X [pii]
LID - 10.1016/j.phrs.2022.106288 [doi]
AB  - Previous studies suggested that probiotics/synbiotics administration exerts some 
      beneficial effects on cardiometabolic risk factors. However, the results from 
      trials have been inconsistent. This study aimed to identify the impact of 
      probiotic and synbiotic supplements on cardiovascular health factors in patients 
      with type 2 diabetes mellitus (T2DM) and prediabetes We searched PubMed/MEDLINE, 
      Web of Science, and Scopus up to February 2022 to identify eligible RCTs. 
      Estimating 95 % confidence (CI) and the weighted mean difference (WMD) for 
      weight, body mass index (BMI), waist circumferences (WC), triglyceride (TG), 
      total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density 
      lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), and diastolic 
      blood pressure (DBP), the random-effects model was used. In the current 
      meta-analysis, 54 RCTs were included. With the probiotic/synbiotics intervention, 
      several parameters changed significantly, including weight (WMD: -0.38, 95 % CI: 
      -0.63 to -0.12 Kg), TG (WMD: -19.08, 95 % CI: -27.65 to -10.51 mg/dl), TC (WMD: 
      -10.46, 95 % CI: -15.19 to -5.72 mg/dl), LDL-C (WMD: -4.87, 95 % CI: -7.65 to 
      -2.09 mg/dl), HDL-C (WMD: -2.70, 95 % CI: 1.33-4.07 mg/dl), SBP (WMD: -3.81, 95 % 
      CI: -6.24 to -1.38 mmHg), and DBP (WMD: -2.01, 95 % CI: -3.12 to -0.91 mmHg). In 
      the subgroup analysis, probiotics/synbiotics supplementation resulted in a 
      greater change in lipid profile components in T2DM patients. Weight and BMI 
      reduced only after synbiotic supplementation. We found that the administration of 
      probiotics and synbiotics had beneficial effects on lipid profiles, 
      anthropometric indices, and blood pressure in individuals with T2DM.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Naseri, Kaveh
AU  - Naseri K
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Saadati, Saeede
AU  - Saadati S
AD  - Department of Medicine, School of Clinical Sciences, Monash University, 
      Melbourne, Australia.
FAU - Yari, Zahra
AU  - Yari Z
AD  - Department of Nutrition Research, National Nutrition and Food Technology Research 
      Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Asbaghi, Omid
AU  - Asbaghi O
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Hezaveh, Zohre Sajadi
AU  - Hezaveh ZS
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Mafi, Davood
AU  - Mafi D
AD  - Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Hoseinian, Pooria
AU  - Hoseinian P
AD  - Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Ashtary-Larky, Damoon
AU  - Ashtary-Larky D
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
FAU - Hekmatdoost, Azita
AU  - Hekmatdoost A
AD  - Department of Clinical Nutrition and Dietetics, National Nutrition and Food 
      Technology Research Institute, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - de Courten, Barbora
AU  - de Courten B
AD  - Department of Medicine, School of Clinical Sciences, Monash University, 
      Melbourne, Australia; School of Health and Biomedical Sciences, RMIT University, 
      Bundoora, Australia. Electronic address: barbora.decourten@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220606
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Triglycerides)
SB  - IM
MH  - *Cardiovascular Diseases/prevention & control
MH  - Cholesterol, HDL
MH  - Cholesterol, LDL
MH  - *Diabetes Mellitus, Type 2
MH  - Dietary Supplements
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - *Prediabetic State
MH  - *Probiotics/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - *Synbiotics
MH  - Triglycerides
OTO - NOTNLM
OT  - Anthropometric indices
OT  - Blood pressure
OT  - Cholesterol (PubChem CID: 5997)
OT  - High-density lipoprotein cholesterol (PubChem CID: 53789179)
OT  - Lipid profile
OT  - Low-density lipoprotein cholesterol (PubChem CID: 53789957)
OT  - Prediabetes
OT  - Probiotic
OT  - Synbiotic
OT  - T2DM
OT  - Triglyceride (PubChem CID: 5460048)
EDAT- 2022/06/10 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/09 19:25
PHST- 2022/04/02 00:00 [received]
PHST- 2022/05/30 00:00 [revised]
PHST- 2022/06/01 00:00 [accepted]
PHST- 2022/06/10 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/09 19:25 [entrez]
AID - S1043-6618(22)00233-X [pii]
AID - 10.1016/j.phrs.2022.106288 [doi]
PST - ppublish
SO  - Pharmacol Res. 2022 Aug;182:106288. doi: 10.1016/j.phrs.2022.106288. Epub 2022 
      Jun 6.